Familial Amyloid Polyneuropathy

Cakar A., Durmus-Tekce H., Parman Y.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.56, sa.2, ss.150-156, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 56 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.29399/npa.23502
  • Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.150-156
  • Anahtar Kelimeler: Transthyretin, genetic, hereditary, treatment, neuropathy, HEREDITARY TRANSTHYRETIN AMYLOIDOSIS, LIVER-TRANSPLANTATION, TTR-FAP, TAFAMIDIS, MANAGEMENT, MANIFESTATIONS, STABILIZATION, PROGRESSION, DIFLUNISAL, PHENOTYPE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is a life-threatening disease caused by the accumulation of amyloidogenic transthyretin (TTR) protein in tissues. Mutations in TTR gene destabilize TTR protein to misfold from its native tetramer form to amyloidogenic monomer form. In endemic countries, TTR-FAP presents with lengthdependent small fiber neuropathy, however in non-endemic countries clinical features can be highly variable. Genetic testing for TTR gene is mandatory for the diagnosis. Demonstrating amyloid deposits in tissues may be necessary for distinguishing symptomatic patients from asymptotuat K. earners. Routine follow-up should include a wide range of tests to demonstrate systemic involvement. In recent years, treatment of TTR-FAP has significantly improved with new therapeutic approaches. TTR stabilizers and TTR-gene silencing drugs prevent the progression of the disease. Monoclonal antibodies that target amyloid deposits are currently under development. Early initiation of the treatment is important for better functional outcome.